Drug Profile


Alternative Names: CL 286558

Latest Information Update: 29 Aug 1997

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Wyeth
  • Class Cytostatics; Platinum complexes
  • Mechanism of Action DNA inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer; Malignant melanoma; Renal cancer

Most Recent Events

  • 29 Aug 1997 Discontinued-II for Malignant melanoma in Norway (Injection)
  • 29 Aug 1997 Discontinued-II for Renal cancer in Norway (Injection)
  • 14 Mar 1995 Discontinued-II for Cancer in Australia (IV-infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top